ANI Pharmaceuticals (ANIP) announced that following final approval from the FDA for its Abbreviated New Drug Application, or ANDA, the Company launched Isosorbide Mononitrate Tablet USP, 10 mg and 20 mg. ANI’s Isosorbide Mononitrate Tablet USP is the generic version of the reference listed drug, or RLD, Monoket.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals announces publication of iluvien clinical trial results
- ANI Pharmaceuticals Highlights Updated Non-GAAP Metrics to Investors
- ANI Pharmaceuticals Signals Strong Growth in 2025 Call
- ANI Pharmaceuticals Posts Record 2025 Results on Rare Disease Growth
- ANI Pharmaceuticals reports Q4 adjusted EPS $2.33, consensus $1.98